Navigation Links
Medicare Establishes Reimbursement Coverage for Vermillion's OVA1(TM) Test
Date:3/12/2010

ducts will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payers such as private insurance companies; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid or Vermillion's ability to relist its shares on the NASDAQ Global Market or on other national securities exchange; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

OVA1(TM) is a trademark of Vermillion Inc.

SOURCE Vermillion, Inc.

Back to top

RELATED LINKS
http://www.vermillion.com

'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QMed, Inc. Reports July Medicare SNP Enrollments
2. Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S.
3. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
4. Medicare Coverage Recommended for In-Home Sleep Testing
5. MedicareCRM(TM) to Speak at IIR Medicare Advantage Congress
6. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
7. Medicare Approves in Home Sleep Apnea Testing
8. Medtronic Unit to Pay $75 Million to Settle Whistleblower Medicare Fraud Case
9. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
10. Arcadian Health Plan Addresses Medicare Doctor Payment Cuts
11. Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing and the Importance of New Medicare-Related E-Prescribing Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Prestwick Pharmaceuticals, Inc., a,privately-held biotechnology company, ... Ph.D. as Executive Vice President, Chief Technology,Officer. ... Prestwick,s pre-clinical,development, regulatory and patent activities around ... candidate, tetrabenazine, a highly,selective and reversible dopamine ...
... of Anesiva,s Needle-Free Technology, SOUTH SAN ... Anesiva, Inc. (Nasdaq: ANSV ) and ... entered into an,agreement granting Particle Therapeutics a ... into its needle-free,intradermal delivery system for glucagon, ...
... Inc.,(Nasdaq: MITI ), a biopharmaceutical company focusing ... cancer, inflammation and,autoimmune diseases, today announced that Dr. ... will present at the Sal. Oppenheim 2nd,European Healthcare ... at 9:50am Eastern time (3:50pm central European time). ...
Cached Biology Technology:Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer 2Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 2Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 3Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 4Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference 2
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... article in PLoS Medicine, Gert Meijer (University Medical Centre Utrecht, ... has been in restoring the function of diseased or damaged ... authors, the use of bone grafts from a different part ... choice for attempting to restore function. But there are ...
... for the adage, ‘All things in moderation.?Researchers at the University ... high-fat meal are more prone to suffer the physical consequences ... Published this month in the Journal of Nutrition, the study ... one group consumed a fast-food breakfast from McDonald’s, the other ...
... Health have developed an experimental vaccine that reduces stillbirths ... common virus that can also cause mental retardation and ... early fetal life. , Estimates place the number of ... 40,000, and there is no vaccine or treatment for ...
Cached Biology News:A steady, high-fat diet is bad, but the news gets worse 2Experimental vaccine given during pregnancy reduces stillbirths from common virus 2Experimental vaccine given during pregnancy reduces stillbirths from common virus 3
BAI-1 (T-20)...
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
GOAT ANTI HUMAN PSA (ISOFORM 1)...
... peptide derived from the N-terminal region of ... Specificity: Specific for the N-terminus of the ... Dog Rat Mouse (positive controls: MDCK-II A431 ... heart blood vessel and brain mossy fiber ...
Biology Products: